New TB vaccine trial aims to stop infection before it starts
NCT ID NCT06050356
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new vaccine called H107e/CAF®10b to prevent tuberculosis (TB). It is the first time this vaccine is given to people. The trial involves 140 healthy adults aged 18 to 45 and checks for side effects and how well the vaccine triggers the immune system. The goal is to train the body to fight TB bacteria without needing antibiotics.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aurum Institute
Pretoria, Gauteng, 0028, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Will a syringe and a vial deliver the same obesity drug dose?
- Can a new injectable drug pass its first human safety test?
- Can exercise rewire bone strength? a new trial investigates
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?